Preclinical evaluation of a urokinase plasminogen activator receptor-targeted nanoprobe in rhesus monkeys
Yushu Chen,1 Li Gong,2 Ning Gao,3 Jichun Liao,1 Jiayu Sun,1 Yuqing Wang,1 Lei Wang,1 Pengjin Zhu,1 Qing Fan,1 Yongqiang Andrew Wang,4 Wen Zeng,2 Hui Mao,3 Lily Yang,5 Fabao Gao11Molecular Imaging Center, Department of Radiology, West China Hospital, Sichuan University, Chengdu, 2Sichuan Primed Bio-T...
Guardado en:
Autores principales: | Chen Y, Gong L, Gao N, Liao J, Sun J, Wang Y, Wang L, Zhu P, Fan Q, Wang YA, Zeng W, Mao H, Yang L, Gao F |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e98eebbcebc4489587b0886faef3e612 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Plasminogen Activator Inhibitor-1 Protects Mice Against Cardiac Fibrosis by Inhibiting Urokinase-type Plasminogen Activator-mediated Plasminogen Activation
por: Kamlesh K. Gupta, et al.
Publicado: (2017) -
Soluble urokinase plasminogen activator receptor as a marker for use of antidepressants.
por: Eva Haastrup, et al.
Publicado: (2014) -
Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator
por: Tobias Kromann-Hansen, et al.
Publicado: (2017) -
Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation
por: Line Jee Hartmann Rasmussen, et al.
Publicado: (2021) -
Soluble Urokinase Plasminogen Activator Receptor (suPAR) Independently Predicts Severity and Length of Hospitalisation in Patients With COVID-19
por: Helena Enocsson, et al.
Publicado: (2021)